Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins

Cancer Research

Volumn 58, Issue 2, 1998, Pages 268-275

  Shen, Ding Wu ^a   Pastan, Ira ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY TARTRATE; ARSENATE SODIUM; ARSENITE SODIUM; CADMIUM CHLORIDE; CELL MEMBRANE PROTEIN; CISPLATIN; DRUG BINDING PROTEIN; METAL; METHOTREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; CROSS RESISTANCE; DRUG UPTAKE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; ARSENICALS; BLOTTING, NORTHERN; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL MEMBRANE; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; METALS; METHOTREXATE; NEOPLASM PROTEINS; RECEPTORS, CELL SURFACE; TUMOR CELLS, CULTURED;

EID: 0031974420     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Richon, V. M., Schulte, N., and Eastman, A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res., 47: 2056-2061, 1987.
2. Loh, S. Y., Mistry P., Kelland, L. R., Abel, G., and Harrap, K. R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br. J. Cancer, 66: 1109-1115, 1992.
3. Johnson, S. W., Shen, D. W., Pastan, I., Gottesman, M. M., and Hamilton, T. C. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp. Cell Res., 226: 133-139, 1996.
4. Moscow, J. A., and Cowan, K. H. Multidrug resistance. J. Natl. Cancer Inst., 80: 14-20, 1988.
5. Kasahra, K., Fujiwara, Y., and Nishio, K. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res., 51: 3237-3242, 1991.
6. Shellard, S. A., Hosking, L. K., and Hill, B. T. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Cancer Res., 51: 4557-4564, 1991.
7. Timmer-Bosscha, H., Mulder, N. H., and de Vries, E. Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br. J. Cancer, 66: 227-238, 1992.
8. Zaman, G. J., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Panlusma, C., Oude Elferink, R. P., Baas, F., and Borst, P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA, 92: 7690-7694, 1995.
9. Godwin, A. K., Meister, A., and Anderson, M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA, 89: 3070-3074, 1992.
10. Newman, E. M., Lu, Y., Kashani-Sabet, M., Kesavan, V., and Scanlon, K. J. Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin. Biochem. Pharmacol., 37: 443-447, 1988.
11. Clugston, C. K., McLaughlin, K., Kenny, M. K., and Brown, R. Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum(II). Cancer Res., 52: 6375-6379, 1992.
12. Zhen, W., Lind, C. J., O'Connor, P. M., Reed E., Parker, R., Howell, S. B., and Bohor, V. A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell. Biol., 12: 3689-3698, 1992.
13. Chu, G. Cellular responses to cisplatin. The role of DNA-binding proteins and DNA repair. J. Biol. Chem., 269: 787-790, 1994.
14. Hettinga, J. V., Lemstra, W., Meijer, C., Los, G., de Vries, E. G., Konings, A. W., and Kampinga, H. H. Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells. Int. J. Cancer. 67: 800-807, 1996.
15. Shen, D. W., Akiyama, S-i., Schoenlein, P., Pastan, I., and Gottesman, M. M. Characterization of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br. J. Cancer, 71: 676-683, 1995.
16. Fanidi, A., Harrington, E. A., and Evan, G. I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (Lond.), 359: 554-556, 1993.
17. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
18. DeFeudis, P., D'Incalci, M., and Broggini, M. Block of bcr-abl expression and induction of apoptosis by cis-platinum in a human chronic myeloid leukemia cell line. Apoptosis, 1: 161-166, 1996.
19. Kondo, S., Barna, B. P, Kondo, Y., Tanaka, Y., Casey, G., Liu, J., Morimura, T., Kaakaji, R., Peterson, J. W., Werbel, B., and Barnett, G. H. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene, 13: 1279-1285, 1996.
20. Minn, A. J., Rudin, C. M., Boise, L. H., and Thompson, C. B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood, 86: 1903-1910, 1995.
21. Hamaguchi, K., Godwin, A. L., Yakushiji, M., O'Dwyer, P. J., Ozols, R. F., and Hamilton, T. C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res., 53: 5225-5232, 1993.
22. Singh, S. V., Xu, B. H., Jani, J. P., Emerson, E. O., Backes, M. G., Rihn, C., Scalamagna, D., Stemmler, N., Specht, S., and Blanock, K. Mechanism of cross resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line. Int. J. Cancer, 61: 431-436, 1995.
23. Parekh, H., and Simpkins, H. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 37: 457-462, 1996.
24. Kelland, L. R., Kimbell, R., Hardcastle, A., Aherne, G. W., and Jackman, A. L. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur. J. Cancer, 31A: 981-986, 1995.
25. Wroblewski, D. H., Bhushan, A., Xuan, Y., Brinton, B. T., Tritton, T. R., and Hacker, M. P. Investigations on the mechanisms of methotrexate resistance in a cisplatin-resistant L1210 murine leukemia cell subline. Cancer Chemother. Pharmacol., 37: 337-342, 1996.
26. 10-propargyl-5,8-dideazafolic acid (CB3717). J. Cancer Res. Clin. Oncol., 117: 519-525, 1991.
27. Kotoh, S., Naito, S., Sakamoto, N., Goto, K., and Kumazawa, J. Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. J. Urol., 152: 1267-1270, 1994.
28. Kondo, Y., Kuo, S. M., Watkins, S. C., and Lazo, J. S. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res., 55: 474-477, 1995.
29. Kelly, S. L., Basu, A., Ticher, B. A., Hacker, M. P., Hamer, D. H., and Lazo, J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science (Washington DC), 241: 1813-1815, 1988.
30. Morton, K. A., Jones, B. J., Shon, M., Datz, F. L., and Lynch, R. E. Enrichment for metallothionein does not confer resistance to cisplatin in transfected NIH/3T3 cells. J. Pharmacol. Exp. Ther., 267: 697-702, 1993.
31. Naredi, P., Heath, D. D., Enns, R. E., and Howell, S. B. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. Cancer Res., 54: 6464-6468, 1994.
32. Naredi, P., Heath, D. D., Enns, R. E., and Howell, S. B. Cross-resistance between cisplatin, antimony potassium tartrate and arsenite in human tumor cells. J. Clin. Invest., 95: 1193-1198, 1995.
33. Ishikawa, T., Bao, J. J., Yamane, Y., Akimaru, K., Frindrich, K., Wright, C. D., and Kuo, M. T. Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells. J. Biol. Chem., 271: 14981-14988, 1996.
34. Jain, N., Lam, Y. M., Pym, J., and Campling, B. G. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer (Phila.), 77: 1797-1808, 1996.
35. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P., and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54: 357-361, 1994.
36. Clifford, S. C., Neal, D. E., and Lunec, J. Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. Br. J. Cancer. 73: 659-666, 1996.
37. Giaccone, G., van Ark-otte, J., Rubio, G. J., Gazdar, A. F., Braxterman, H. J., Fleus, M. J., Scheper, R. J., and Pinedo, H. M. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int. J. Cancer, 66: 760-767, 1996.
38. 74As-labeled arsenate and arsenite for use in biological experiments. Anal. Biochem., 78: 557-560, 1977.
39. Cornwell, M. M., Tsuruo, T., Gottesman, M. M., and Pastan, I. ATP-binding properties of P-glycoprotein from multidrug-resistant KB cells. FASEB J., 1: 51-54, 1987.
40. Mantovani, L. T., Miotti, S., Menard, S., Canevari, S., Raspagliesi, F., Bottinit, C., Bottero, F., and Colnaghi, M. I. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J. Cancer, 30A: 363-369, 1994.
41. Shen, D. W., Fojo, A., Chin, J. E., Roninson, I. B., Richert, N., Pastan, I., and Gottesman, M. M. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science (Washington DC), 232: 643-645, 1986.
42. Elwood, P. C. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J. Biol. Chem., 264: 14893-14901, 1989.
43. Huang, R. N., and Lee, T. C. Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Toxicol. Appl. Pharmacol., 136: 243-249, 1996.
44. Gottesman, M. M., Hrycyna, C. A., Schoenlein, P. V., Germann, U. A. and Pastan, I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet., 29: 607-649, 1995.
45. Cole, S. P., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., and Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 54: 5902-5910, 1994.
46. Gorlick, R., Goker, E., Trippett, T., Waltham, M., Banerjee, D., and Bertino, J. R. Intrinsic and acquired resistance to methotrexate in acute leukemia. Drug Therapy. 335: 1041-1048, 1996.
47. de Graaf, D., Sharma, R. C., Mechetner, E. B., Schimke, R. T., and Roninson, I. B. P-Glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc. Natl. Acad. Sci. USA, 93: 1238-1242, 1996.
48. Norris, M. D., Graaf, D. D., Haber, M., Kavallaris, M., Madafiglio, J., Gilbert, J., Kwan, E., Stewart, B. N., Mechetner, E. B., Gudkor, A. V., and Roninson, I. B. Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int. J. Cancer, 65: 613-619, 1996.
49. Saolawa, Y., Knight, C. B., Saikawa, T., Page, T. P., Chabner, B. A., and Elwood, P. C. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells. J. Biol. Chem., 268: 5293-5301, 1993.
50. Moscow, J. A., Gong, M., He, R., Sgagias, M. K., Dixon, K. H., Anzick, S. L., Meltzer, P. S., and Cowan, K. H. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res., 55: 3790-3794, 1995.
51. Frederick, M. R., and Flintoff, W. F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J. Biol. Chem., 270: 2987-2992, 1995.
52. Hsueh, C. T., and Dolnick, B. J. Regulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cells. Biochem. Pharmacol., 47: 1019-1027, 1994.
53. Silver, S., and Ji, G. Newer systems for bacterial resistance to toxic heavy metals. Environ. Health Perspect., 12 (Suppl. 3): 107-113, 1994.
54. Li, Z., Szczypka, M., Lu, Y., Thiels, D. J., and Rea, P. A. The yeast cadmium factor protein (YCF1) is a vacuolar glutathione S-conjugate pump. J. Biol. Chem., 271: 6509-6517, 1996.
55. Grondin, K., Papadopoulou, B., and Ouellette, M. Homologous recombination between direct repeat sequences yields P-glycoprotein containing amplicons in arsenite resistant leishmania. Nucleic Acids Res., 21: 1895-1901, 1993.
56. Dey, S., Dou, D., and Rosen, B. P. ATP-dependent arsenite transport in everted membrane vesicles of Escherichia coli. J. Biol. Chem., 269: 25442-25446, 1994.
57. Yang, Y. Y., Woo, E. S., Reese, C. E., Bahnson, R. R., Saijo, N., and Lazo, J. S. Human metallothionein isoform gene expression in cisplatin-sensitive and resistant cells. Mol. Pharmacol., 45: 453-460, 1994.
58. Nies, D. H., and Silver, S. Ion efflux systems involved in bacterial metal resistance. J. Indust. Microbiol., 14: 186-199, 1995.
59. Legare, D., Hettema, E., and Ouellette, M. The P-glycoprotein-related gene family in leishmania. Mol. Biochem. Parasitol., 68: 81-91, 1994.
60. Callahan, H. L., Roberts, W. L., Rainey, P. M., and Beverley, S. M. The PGPA gene of Leishmania major mediates antimony (SbIII) resistance by decreasing influx and not by increasing efflux. Mol. Biochem. Parasitol., 68: 145-149, 1994.
61. Wang, T. S., and Huang, H. Active oxygen species are involved in the induction of micronuclei by arsenite in XRS-5 cells. Mutagenesis, 9: 253-257, 1994.
62. Huang, R. N., Ho, I. C., Yin, L. H., and Lee, T. C. Sodium arsenite induces chromosome endoreduplication and inhibits protein phosphatase activity in human fibroblasts. Environ. Mol. Mutagen., 25: 188-196, 1995.
63. Jekunen, A. P., Hom, D. K., Alcaraz, J. E., Eastman, A., and Howell, S. B. Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells. Cancer Res., 54: 2680-2687, 1994.
64. Gately, D. P., and Howell, S. B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer, 67: 1171-1176, 1993.